市场调查报告书
商品编码
1467572
2024-2032 年医疗保健市场人工智慧报告(按产品、技术、应用、最终用户和地区划分)Artificial Intelligence in Healthcare Market Report by Offering, Technology, Application, End-User, and Region 2024-2032 |
IMARC Group年,全球人工智慧医疗保健市场规模达到61亿美元。对个人化药物的需求不断增长、远端患者监测设施的日益普及,以及用于分析医学影像、检测异常和有效预测患者结果的机器学习(ML) 技术的不断进步,是推动市场发展的一些主要因素。
医疗保健中的人工智慧(AI)是应用智慧演算法和计算模型来分析复杂的医疗资料、辅助诊断和治疗并支援医疗保健决策过程。它涵盖各种人工智慧技术,包括机器学习 (ML)、自然语言处理 (NLP)、电脑视觉和专家系统。它分析大量患者资料,包括电子健康记录 (EHR)、医学影像和基因组资料,以识别模式并做出预测。它有助于早期疾病检测、个人化治疗计划和临床决策支援。此外,它可以根据资料分析提供有价值的见解和建议,帮助医疗保健专业人员做出基于证据的决策。
目前,医疗保健领域对人工智慧的需求不断增加,因为它改善了医学研究和药物开发流程,正在推动市场的成长。除此之外,医疗保健产业产生的资料量不断增加,包括数位电子病历、医学影像和基因组讯息,也促进了市场的成长。此外,用于有效分析医学影像、检测异常和预测患者结果的机器学习技术的不断进步也带来了良好的市场前景。除此之外,对临床决策支援系统的需求不断增长,这些系统提供基于证据的建议和治疗指南,并帮助医疗保健专业人员做出准确和明智的决策,这正在支持市场的成长。此外,许多国家的管理机构不断实施促进人工智慧在医疗保健领域采用的政策和激励措施,这也促进了市场的成长。
个人化药物需求不断成长
个人化药物是根据个人的独特特征(例如遗传、生活方式和病史)量身定制的。透过考虑这些因素,与传统的一刀切的方法相比,个人化药物在治疗特定疾病方面具有更有效的潜力。除此之外,个人化药物旨在根据每个患者的特定特征提供有针对性的治疗,从而实现更准确的诊断和量身定制的治疗。此外,人工智慧在个人化药物开发中的整合正在提高製程的准确性。它还有助于识别特定的生物标记物,旨在根据每位患者的特定特征提供有针对性的治疗,从而实现更准确的诊断和量身定制的治疗。
远距患者监护日益普及
远端患者监控使个人能够在舒适的家中追踪他们的健康状况,从而无需频繁前往医疗机构。这限制了旅行、候诊室和其他与医疗保健相关的不便,从而提高了患者满意度。它提高了医疗保健的可及性,特别是对于那些偏远或服务欠缺地区的人来说,使患者能够与医疗保健提供者联繫并获得高品质的护理,无论他们身在何处。透过采用与人工智慧 (AI) 整合的医疗设备进行即时监控,使医疗保健提供者能够及时发现患者健康状况的任何异常或偏差。医疗保健领域的人工智慧透过提高流程的有效性和效率,在远端患者监控中发挥着至关重要的作用。
群众中慢性疾病的发生率增加
目前,由于久坐、体力活动减少和不健康的饮食习惯等不活跃的生活方式引起的慢性病盛行率上升。这些生活方式因素导致肥胖、糖尿病和心血管疾病等疾病的出现。此外,不良的饮食选择,包括过量食用加工食品、含糖饮料和饱和脂肪含量高的食物,也会导致慢性疾病的发生。慢性病的增加也推动了住院率的上升,以及对结合人工智慧的有效治疗方法的需求。医疗保健领域的人工智慧正在改善各种慢性疾病的筛检过程和检测。它还帮助医疗保健专业人员做出正确的决定和准确的诊断。
The global artificial intelligence in healthcare market size reached US$ 6.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 57.2 Billion by 2032, exhibiting a growth rate (CAGR) of 27.4% during 2024-2032. The growing demand for personalized medications, rising popularity of remote patient monitoring facilities, and increasing advancements in machine learning (ML) techniques for analyzing medical images, detecting anomalies, and predicting patient outcomes efficiently are some of the major factors propelling the market.
Artificial intelligence (AI) in healthcare is the application of intelligent algorithms and computational models to analyze complex medical data, assist in diagnosis and treatment, and support healthcare decision-making processes. It encompasses various AI techniques, including machine learning (ML), natural language processing (NLP), computer vision, and expert systems. It analyzes large volumes of patient data, including electronic health records (EHR), medical images, and genomic data, to identify patterns and make predictions. It aids in early disease detection, personalized treatment planning, and clinical decision support. Furthermore, it can assist healthcare professionals in making evidence-based decisions by providing valuable insights and recommendations based on data analysis.
At present, the increasing demand for AI in healthcare as it improves medical research and drug development processes is impelling the growth of the market. Besides this, the rising amount of data generated in the healthcare industry, including digital EHR, medical images, and genomic information, is contributing to the growth of the market. In addition, the growing advancements in ML techniques for efficiently analyzing medical images, detecting anomalies, and predicting patient outcomes are offering a favorable market outlook. Apart from this, the increasing demand for clinical decision support systems that offer evidence-based recommendations and treatment guidelines and assist healthcare professionals in making accurate and informed decisions is supporting the growth of the market. Additionally, the rising implementation of policies and incentives by governing agencies of numerous countries to promote the adoption of AI in healthcare is bolstering the growth of the market.
Rising demand for personalized medications
Personalized medications are tailored to the unique characteristics of individuals, such as genetics, lifestyle, and medical history. By considering these factors, personalized medications possess the potential to be more effective in treating specific conditions compared to traditional one-size-fits-all approaches. Besides this, personalized medications aim to deliver targeted treatments based on the specific characteristics of each patient, allowing for more accurate diagnoses and tailored therapies. In addition, the integration of AI in the development of personalized medication is improving the accuracy of the process. It is also helping in identifying specific biomarkers that aim to deliver targeted treatments based on the specific characteristics of each patient, allowing for more accurate diagnoses and tailored therapies.
Increasing popularity of remote patient monitoring
Remote patient monitoring enables individuals to track their health from the comfort of their own homes, eliminating the need for frequent trips to healthcare facilities. This limits the inconvenience of travel, waiting rooms, and other healthcare-related inconveniences, leading to improved patient satisfaction. It enhances healthcare accessibility, particularly for those in remote or underserved areas, allowing patients to connect with healthcare providers and receive high-quality care regardless of their location. Real-time monitoring by employing medical devices integrated with artificial intelligence (AI) enables healthcare providers to promptly detect any abnormalities or deviations in patient health. AI in healthcare plays a crucial role in remote patient monitoring by enhancing the effectiveness and efficiency of the process.
Increasing occurrence of chronic disorders among the masses
Presently, there is a rise in the prevalence of chronic illnesses caused by inactive lifestyles, such as prolonged sitting, decreased physical activity, and unhealthy eating habits. These lifestyle factors contribute to the emergence of conditions like obesity, diabetes, and cardiovascular diseases. In addition, poor dietary choices involving excessive consumption of processed foods, sugary drinks, and foods high in saturated fats also contribute to the development of chronic ailments. The increase in chronic diseases is also driving hospitalization rates and the demand for effective treatment methods by incorporating AI. AI in healthcare is improving the screening process and detection of various chronic disorders. It is also assisting healthcare professionals to make the correct decision and accurate diagnoses.
IMARC Group provides an analysis of the key trends in each segment of the global artificial intelligence in healthcare market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on offering, technology, application, and end-user.
Hardware
Software
Services
Software dominates the market
The report has provided a detailed breakup and analysis of the market based on the offering. This includes hardware, software, and services. According to the report, software represented the largest segment.
Software associated with AI in healthcare comprises electronic health record (EHR) systems, imaging analysis software, clinical decision support systems (CDSS), and natural language processing (NPL) tools. They digitally store and manage patient health records and analyze and extract valuable insights from the vast amount of patient data, facilitating decision-making, personalized treatment planning, and clinical research. They utilize computer vision and machine learning (ML) algorithms to assist radiologists in detecting abnormalities, making diagnoses, and providing quantitative measurements. They can extract relevant information, classify and categorize text, and enable voice-to-text transcription. They also enable continuous monitoring of vital signs, activity levels, and other health parameters to predict health deterioration and alert healthcare providers in real-time.
Machine Learning
Context Aware Computing
Natural Language Processing
Others
Machine learning holds the largest share in the market
A detailed breakup and analysis of the market based on the technology have also been provided in the report. This includes machine learning, context aware computing, natural language processing, and others. According to the report, machine learning accounted for the largest market share.
Machine learning (ML) algorithms are employed to analyze patient data, such as electronic health records (EHR), medical imaging, and genetic information, to assist in disease diagnosis and prognosis. These algorithms identify patterns, classify diseases, and predict patient outcomes, aiding healthcare professionals in making accurate and timely decisions. They are capable of detecting abnormalities, segmenting organs and tumors, and assisting radiologists in interpreting images. ML-based image analysis improves diagnostic accuracy, reduces interpretation time, and enhances early detection of diseases. ML models also predict patient outcomes by analyzing large datasets, including clinical records, genomic data, and lifestyle factors. Furthermore, they can analyze EHR to uncover valuable insights, such as disease trends, treatment patterns, and population health indicators.
Robot-Assisted Surgery
Virtual Nursing Assistant
Administrative Workflow Assistance
Fraud Detection
Dosage Error Reduction
Clinical Trial Participant Identifier
Preliminary Diagnosis
Others
Clinical trial participant identifier holds the biggest share in the market
A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes robot-assisted surgery, virtual nursing assistant, administrative workflow assistance, fraud detection, dosage error reduction, clinical trial participant identifier, preliminary diagnosis, and others. According to the report, clinical trial participant identifier accounted for the largest market share.
A clinical trial participant identifier is assigned to individuals enrolled in a clinical trial to protect their privacy and confidentiality. It is used instead of personal identifying information (such as name or social security number) to ensure anonymity and protect the identity of participants. It helps ensure data integrity and security in clinical trials. By using identifiers instead of personal information, the potential for data errors or inconsistencies due to human error or data entry mistakes is reduced. It also helps protect sensitive information from being inadvertently disclosed or misused.
Robot-assisted surgery, also known as robotic surgery, refers to a surgical technique that utilizes robotic systems to aid surgeons in performing complex procedures with enhanced precision, dexterity, and control. It involves the use of robotic arms, specialized instruments, and a computer console operated by a surgeon.
Healthcare Providers
Pharmaceutical and Biotechnology Companies
Patients
Others
Pharmaceutical and biotechnology companies hold the maximum share in the market
A detailed breakup and analysis of the market based on the end-user have also been provided in the report. This includes healthcare providers, pharmaceutical and biotechnology companies, patients, and others. According to the report, pharmaceutical and biotechnology companies accounted for the largest market share.
Pharmaceutical and biotechnology companies are embracing the use of AI due to its transformative potential across various aspects of their operations. AI offers unprecedented opportunities to revolutionize drug discovery and development processes by leveraging data-driven approaches and computational modeling. Through AI algorithms, these companies can analyze vast amounts of biological and chemical data to identify potential drug targets, predict drug activity, and optimize drug design, significantly speeding up the traditionally time-consuming and expensive drug development pipeline. Additionally, AI enables precision medicine by leveraging patient data, genomics, and clinical records to develop personalized treatment approaches. AI algorithms can identify biomarkers or genetic variations associated with disease susceptibility and treatment response, allowing for targeted therapies and patient subgroup identification.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest artificial intelligence in healthcare market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America held the biggest market share since the region has an efficient medical infrastructure. Moreover, the rising occurrence of various chronic disorders among the masses is contributing to the growth of the market.
Another contributing aspect is the growing adoption of robust technology infrastructure, including advanced computing capabilities, cloud computing resources, and data storage capacities in the healthcare sector.
Asia Pacific is estimated to expand further in this domain due to the rising construction of various hospitals, clinics, and nursing homes to provide quality healthcare services. Apart from this, increasing healthcare expenditures among the masses is propelling the market growth.
Key market players are investing in research operations to improve their AI capabilities. They are also allocating significant resources to develop new algorithms, models, and platforms that can enhance the accuracy, efficiency, and effectiveness of AI applications in healthcare. Top companies are expanding and diversifying their product portfolios to meet evolving market needs. They are also developing and launching new AI-powered solutions and platforms for various healthcare domains, including diagnostic imaging, clinical decision support, remote patient monitoring, genomics, and drug discovery. Leading companies are focusing on strategic partnerships and collaborations to enhance their market reach, access new customer segments, and leverage complementary technologies.
Amazon Web Services Inc.
Cloudmedx Inc.
DeepMind
Enlitic Inc.
General Vision Inc.
Google Inc.
International Business Machines
iCarbonX
Intel Corporation
Medtronic
Micron Technology Inc.
Microsoft Corporation
Next It Corporation
Nuance Communications Inc.
Nvidia Corporation
Siemens Healthcare
Welltok Inc.
In March 2023, Medtronic plc announced a strategic collaboration with Cosmo Pharmaceutical and Nvidia Corporation to deliver the GI Genius(TM) intelligent endoscopy module - the first FDA-cleared, AI-assisted colonoscopy tool to help physicians detect polyps that can lead to colorectal cancer.
In March 2023, Nvidia Corporation announced the launch of an expanded set of generative AI cloud services for customizing AI foundation models to accelerate the production of novel proteins and therapeutics.
In November 2022, Nuance Communications Inc. announced a partnership with Nvidia Corporation for bringing medical imaging AI models directly into clinical settings and improving patient care solutions.